Claims for RU <strong>486</strong>/PG Abortionthe British trials admits that, ‘To maintain safety you requireextremely close medical supervision’ (Sunday Times, 30October 1988).How, then, are women presumed to control this newabortion method? What is the privacy <strong>and</strong> de-medicalizationthat has been so touted in the promotional literature? Privacy<strong>and</strong> control by what/whose st<strong>and</strong>ards? In the minds of many,both privacy <strong>and</strong> control seem to be equated with any methodthat is non-conventional. In reality, the RU <strong>486</strong>/PG abortionmethod increases, rather than decreases, the lack of privacy<strong>and</strong> the lack of women’s control over the abortion experience.The only thing different about an RU <strong>486</strong>/PG abortion isthe rhetoric of control which hardly matches the reality of strict<strong>and</strong> prolonged medical supervision. Measured by the numberof doctor’s visits, <strong>and</strong> the duration of time from visit one tovisit three, or four (at which point the woman is back tosquare one of conventional abortion), we are talking about anon-private, extensively medicalized, <strong>and</strong> complicatedabortion method.Additionally, the anonymity of a woman’s abortion isprecluded by registration. Under French law, the abortionpill’s use is tightly controlled. It is administered solely atdesignated family planning centers—the only place any typeof abortion can be performed there—<strong>and</strong> is not available fromindividual doctors or pharmacies. In Engl<strong>and</strong>, the nextcountry where RU <strong>486</strong>/PG is to be distributed <strong>and</strong> marketed,the 1967 Abortion Act requires that abortion technology <strong>and</strong>drugs be given exclusively in hospitals <strong>and</strong> clinics licensedunder the act. Furthermore, all the trials have been closelycontrolled as in France, not simply because they are trialsbut, as many of the researchers <strong>and</strong> clinicians readily admit,because RU <strong>486</strong>/PG is not safe enough to administer withoutclose medical supervision. What happens, now, to EllenGoodman’s original question: ‘How could a state controlswallowing?’ Easily, when a country, even for the best of29
RU <strong>486</strong>reasons, controls the procedur e in the way that France,Engl<strong>and</strong>, <strong>and</strong> others currently do.Likewise, the Fund for Feminist Majority, which hasconducted an international campaign to bring RU <strong>486</strong>/PGto the United States, claims that the pill would divest antiabortiongroups of ‘one of their most effective tactics—openharassment <strong>and</strong> violence at abortion clinics. Because RU <strong>486</strong>can be administered at any doctor’s office—not just at abortionclinics-picketing becomes meaningless!’ (The FeministMajority Foundation Communiqué, 1990). RU <strong>486</strong>/ PG hasalso been represented in the feminist press as being availablefrom ‘the local pharmacy’ <strong>and</strong> thereby ‘technologicallybypassing’ the anti-abortion movement This claim is blatantlymisleading since nowhere is RU <strong>486</strong> administered at ‘anydoctor’s office.’ Nor do hospitals <strong>and</strong> other medical servicessimply dispense RU <strong>486</strong>/PG. It is only administered as amulti-step, on-the-premise procedure. These medical services,among them many clinics, can be picketed just as easily asthe present conventional abortion clinics. Tony Seaton ofRoussel Uclaf UK deplores that the general public incorrectlybelieves that RU <strong>486</strong> will be available from GPs. Hereconfirmed that every pill will be numbered to ensure thestrictest possible control <strong>and</strong> total restriction to licensedabortion clinics (pers. comm. to RK, 26 June 1991).Doctors assert that the abortion pill will not be availableat the pharmacy because it requires strict medical supervision,at the same time that they proclaim that RU <strong>486</strong>/PG is asafe, streamlined, <strong>and</strong> privatized means of abortion forwomen. In an interview in the Los Angeles Times, David Grimesadmitted that although he believes, ‘We’ve got to get doctors<strong>and</strong> medical people out of the process,’ he likes the stringentcontrols that now surround the drug (Grimes, quoted in Krier,1990: E-12). But many feminists seem to believe that womenwill control the drug, <strong>and</strong> that the RU <strong>486</strong> abortionexperience relieves women of the burdens of interventionistmedicine <strong>and</strong> anti-abortion harassment There appears to be30
- Page 2 and 3: Renate Klein is Lecturer in Women
- Page 4 and 5: RU 486Misconceptions,Myths and Mora
- Page 6 and 7: ACKNOWLEDGEMENTSWe would like to ex
- Page 8 and 9: CONTENTSINTRODUCTION 1CHAPTER ONETh
- Page 10 and 11: INTRODUCTIONInitial euphoria greete
- Page 12 and 13: IntroductionUnfortunately, objectio
- Page 14 and 15: Introductiondo not know or do not a
- Page 16 and 17: Introductionused widely for years a
- Page 18 and 19: CHAPTER ONEThe History of RU 486RU
- Page 20 and 21: The History of RU 486consultants ar
- Page 22 and 23: The History of RU 486Events in Fran
- Page 24 and 25: The History of RU 486service of wom
- Page 26 and 27: The History of RU 486The result app
- Page 28 and 29: The History of RU 486developing cou
- Page 30 and 31: The History of RU 486University Hos
- Page 32 and 33: The History of RU 486pharmacovigila
- Page 34 and 35: CHAPTER TWOClaims for RU 486/PG Abo
- Page 36 and 37: Claims for RU 486/PG Abortionsevera
- Page 40 and 41: Claims for RU 486/PG Abortionan imm
- Page 42 and 43: Claims for RU 486/PG Abortionby the
- Page 44 and 45: Claims for RU 486/PG Abortionby the
- Page 46 and 47: Claims for RU 486/PG Abortionfrom A
- Page 48 and 49: Claims for RU 486/PG Abortioncommen
- Page 50 and 51: Claims for RU 486/PG AbortionSome s
- Page 52 and 53: Claims for RU 486/PG Abortionbreeze
- Page 54 and 55: Claims for RU 486/PG Abortion18 per
- Page 56 and 57: Claims for RU 486/PG Abortion1. RU
- Page 58 and 59: Claims for RU 486/PG AbortionRU 486
- Page 60 and 61: Claims for RU 486/PG Abortionwider
- Page 62 and 63: Claims for RU 486/PG Abortionmedica
- Page 64 and 65: Claims for RU 486/PG Abortionreligi
- Page 66 and 67: What Is RU 486 and How Does It Work
- Page 68 and 69: What Is RU 486 and How Does It Work
- Page 70 and 71: What Is RU 486 and How Does It Work
- Page 72 and 73: What Is RU 486 and How Does It Work
- Page 74 and 75: What Is RU 486 and How Does It Work
- Page 76 and 77: What Is RU 486 and How Does It Work
- Page 78 and 79: What Is RU 486 and How Does It Work
- Page 80 and 81: What Is RU 486 and How Does It Work
- Page 82 and 83: What Is RU 486 and How Does It Work
- Page 84 and 85: What Is RU 486 and How Does It Work
- Page 86 and 87: What Is RU 486 and How Does It Work
- Page 88 and 89:
What Is RU 486 and How Does It Work
- Page 90 and 91:
The Role of Prostaglandins: Known a
- Page 92 and 93:
The Role of Prostaglandins: Known a
- Page 94 and 95:
The Role of Prostaglandins: Known a
- Page 96 and 97:
The Role of Prostaglandins: Known a
- Page 98 and 99:
The Role of Prostaglandins: Known a
- Page 100 and 101:
The Role of Prostaglandins: Known a
- Page 102 and 103:
The Role of Prostaglandins: Known a
- Page 104 and 105:
The Role of Prostaglandins: Known a
- Page 106 and 107:
The Role of Prostaglandins: Known a
- Page 108 and 109:
The Role of Prostaglandins: Known a
- Page 110 and 111:
The Role of Prostaglandins: Known a
- Page 112 and 113:
The Role of Prostaglandins: Known a
- Page 114 and 115:
The Role of Prostaglandins: Known a
- Page 116 and 117:
The Role of Prostaglandins: Known a
- Page 118 and 119:
The Role of Prostaglandins: Known a
- Page 120 and 121:
The Role of Prostaglandins: Known a
- Page 122 and 123:
ConclusionInstead, Baulieu uses the
- Page 124 and 125:
Conclusionintervention. Thus, RU 48
- Page 126 and 127:
Conclusionbetween population contro
- Page 128 and 129:
ConclusionThis article, appearing i
- Page 130 and 131:
Conclusion‘a whole net of relatio
- Page 132 and 133:
ENDNOTESChapter One1The paten t lic
- Page 134 and 135:
Endnotes12The Journal Officiel publ
- Page 136 and 137:
Endnotesin Gynecology and Obstetric
- Page 138 and 139:
Endnotesof menses. On the third day
- Page 140 and 141:
EndnotesAnother such example is the
- Page 142 and 143:
Bibliographyand Segal, Sheldon (Eds
- Page 144 and 145:
Bibliographyprostaglandin F 2•. A
- Page 146 and 147:
BibliographyDelaney, Anne. (1991, 2
- Page 148 and 149:
Bibliographyresponses to the steroi
- Page 150 and 151:
Bibliographyabnormalities resulting
- Page 152 and 153:
Bibliographyprogesterone receptor b
- Page 154 and 155:
BibliographyOdlind, Viveca and Birg
- Page 156 and 157:
BibliographyBinding of the anti-pro
- Page 158 and 159:
BibliographyUlmann, André, Teutsch
- Page 160:
Bibliographytermination by vacuum a